These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. CXCR2--the receptor to hit? Reutershan J Drug News Perspect; 2006 Dec; 19(10):615-23. PubMed ID: 17299604 [TBL] [Abstract][Full Text] [Related]
26. Synthesis, Structure-Activity Relationship Studies, and ADMET Properties of 3-Aminocyclohex-2-en-1-ones as Chemokine Receptor 2 (CXCR2) Antagonists. Dai W; Chen W; Debnath B; Wu Y; Neamati N ChemMedChem; 2018 May; 13(9):916-930. PubMed ID: 29493096 [TBL] [Abstract][Full Text] [Related]
27. Targeting both tumour-associated CXCR2 Nywening TM; Belt BA; Cullinan DR; Panni RZ; Han BJ; Sanford DE; Jacobs RC; Ye J; Patel AA; Gillanders WE; Fields RC; DeNardo DG; Hawkins WG; Goedegebuure P; Linehan DC Gut; 2018 Jun; 67(6):1112-1123. PubMed ID: 29196437 [TBL] [Abstract][Full Text] [Related]
28. Small molecule antagonists for chemokine CCR3 receptors. Willems LI; Ijzerman AP Med Res Rev; 2010 Sep; 30(5):778-817. PubMed ID: 19967721 [TBL] [Abstract][Full Text] [Related]
29. Pyrimidine-based compounds modulate CXCR2-mediated signaling and receptor turnover. Ha H; Neamati N Mol Pharm; 2014 Jul; 11(7):2431-41. PubMed ID: 24896229 [TBL] [Abstract][Full Text] [Related]
30. Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Zheng Y; Qin L; Zacarías NV; de Vries H; Han GW; Gustavsson M; Dabros M; Zhao C; Cherney RJ; Carter P; Stamos D; Abagyan R; Cherezov V; Stevens RC; IJzerman AP; Heitman LH; Tebben A; Kufareva I; Handel TM Nature; 2016 Dec; 540(7633):458-461. PubMed ID: 27926736 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2). Strunz AK; Zweemer AJ; Weiss C; Schepmann D; Junker A; Heitman LH; Koch M; Wünsch B Bioorg Med Chem; 2015 Jul; 23(14):4034-49. PubMed ID: 25766632 [TBL] [Abstract][Full Text] [Related]
32. Synthesis and structure-activity relationship of 7-azaindole piperidine derivatives as CCR2 antagonists. Xia M; Hou C; DeMong D; Pollack S; Pan M; Singer M; Matheis M; Murray W; Cavender D; Wachter M Bioorg Med Chem Lett; 2008 Dec; 18(24):6468-70. PubMed ID: 18990568 [TBL] [Abstract][Full Text] [Related]
33. Assessment of chemokine receptor function on monocytes in whole blood: In vitro and ex vivo evaluations of a CCR2 antagonist. Wisniewski T; Bayne E; Flanagan J; Shao Q; Wnek R; Matheravidathu S; Fischer P; Forrest MJ; Peterson L; Song X; Yang L; Demartino JA; Struthers M J Immunol Methods; 2010 Jan; 352(1-2):101-10. PubMed ID: 19913021 [TBL] [Abstract][Full Text] [Related]
34. Identification of a novel allosteric binding site in the CXCR2 chemokine receptor. de Kruijf P; Lim HD; Roumen L; Renjaän VA; Zhao J; Webb ML; Auld DS; Wijkmans JC; Zaman GJ; Smit MJ; de Graaf C; Leurs R Mol Pharmacol; 2011 Dec; 80(6):1108-18. PubMed ID: 21948388 [TBL] [Abstract][Full Text] [Related]
35. Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists. Junker A; Kokornaczyk AK; Zweemer AJ; Frehland B; Schepmann D; Yamaguchi J; Itami K; Faust A; Hermann S; Wagner S; Schäfers M; Koch M; Weiss C; Heitman LH; Kopka K; Wünsch B Org Biomol Chem; 2015 Feb; 13(8):2407-22. PubMed ID: 25566983 [TBL] [Abstract][Full Text] [Related]
36. Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists. Austin RP; Bennion C; Bonnert RV; Cheema L; Cook AR; Cox RJ; Ebden MR; Gaw A; Grime K; Meghani P; Nicholls D; Phillips C; Smith N; Steele J; Stonehouse JP Bioorg Med Chem Lett; 2015 Apr; 25(7):1616-20. PubMed ID: 25708618 [TBL] [Abstract][Full Text] [Related]
37. Design, synthesis, and structure-activity relationship of novel CCR2 antagonists. Kothandaraman S; Donnely KL; Butora G; Jiao R; Pasternak A; Morriello GJ; Goble SD; Zhou C; Mills SG; Maccoss M; Vicario PP; Ayala JM; Demartino JA; Struthers M; Cascieri MA; Yang L Bioorg Med Chem Lett; 2009 Mar; 19(6):1830-4. PubMed ID: 19237282 [TBL] [Abstract][Full Text] [Related]
38. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889 [TBL] [Abstract][Full Text] [Related]
39. CXCR2 is essential for cerebral endothelial activation and leukocyte recruitment during neuroinflammation. Wu F; Zhao Y; Jiao T; Shi D; Zhu X; Zhang M; Shi M; Zhou H J Neuroinflammation; 2015 May; 12():98. PubMed ID: 25990934 [TBL] [Abstract][Full Text] [Related]